Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable...

Cite
Trinh A, Khamari R, Fovez Q, et al. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021;55:101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 55101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells." Molecular metabolism vol. 55 (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941; PMCID: PMC8732793.
Copy Download .nbib Format: NLM
ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective treatment for chronic myeloid leukemia (CML) and discontinuation of TKI therapy is now being proposed to patients with deep molecular responses. However, evidence demonstrating that TKI are unable to...

Cite
Trinh A, Khamari R, Fovez Q, et al. ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Mol Metab. 2021;101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Molecular metabolism, 101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS." Molecular metabolism vol. (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941.
Copy Download .nbib Format: NLM
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective treatment for chronic myeloid leukemia (CML) and discontinuation of TKI therapy is now being proposed to patients with deep molecular responses. However, evidence demonstrating that TKI are unable to...

Cite
Trinh A, Khamari R, Fovez Q, et al. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021;101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells." Molecular metabolism vol. (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941.
Copy Download .nbib Format: NLM
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2022 Jan;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable...

Cite
Trinh A, Khamari R, Fovez Q, et al. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021;55:101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2022). Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 55101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells." Molecular metabolism vol. 55 (2022): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2022 Jan;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941; PMCID: PMC8732793.
Copy Download .nbib Format: NLM
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2022 Jan;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable...

Cite
Trinh A, Khamari R, Fovez Q, et al. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021;55:101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2022). Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 55101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells." Molecular metabolism vol. 55 (2022): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2022 Jan;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941; PMCID: PMC8732793.
Copy Download .nbib Format: NLM
A new species in the genus Amphipteryx Selys, 1853 (Odonata, Amphipterygidae) from Pico Bonito National Park, Honduras.

ZooKeys

Jocque M, Argueta I.
PMID: 24899838
Zookeys. 2014 May 13;(408):71-80. doi: 10.3897/zookeys.408.7174. eCollection 2014.

The Mesoamerican damselfly genus Amphipteryx includes four species: Amphipteryx agrioides (Mexico), A. chiapensis (Mexico), A. meridionalis (Honduras) and A. nataliae (Verapaz, Guatemala). We describe a fifth species, Amphipteryx jaroli, from the cloud forest in Pico Bonito National park, Honduras....

Cite
Jocque M, Argueta I. A new species in the genus Amphipteryx Selys, 1853 (Odonata, Amphipterygidae) from Pico Bonito National Park, Honduras. Zookeys. 2014;(408):71-80doi: 10.3897/zookeys.408.7174.
Jocque, M., & Argueta, I. (2014). A new species in the genus Amphipteryx Selys, 1853 (Odonata, Amphipterygidae) from Pico Bonito National Park, Honduras. ZooKeys, (408), 71-80. https://doi.org/10.3897/zookeys.408.7174
Jocque, Merlijn, and Argueta, Ivany. "A new species in the genus Amphipteryx Selys, 1853 (Odonata, Amphipterygidae) from Pico Bonito National Park, Honduras." ZooKeys vol. ,408 (2014): 71-80. doi: https://doi.org/10.3897/zookeys.408.7174
Jocque M, Argueta I. A new species in the genus Amphipteryx Selys, 1853 (Odonata, Amphipterygidae) from Pico Bonito National Park, Honduras. Zookeys. 2014 May 13;(408):71-80. doi: 10.3897/zookeys.408.7174. eCollection 2014. PMID: 24899838; PMCID: PMC4042827.
Copy Download .nbib Format: NLM
An Integrated Enzymatic Approach to Produce Pentyl Xylosides and Glucose/Xylose Laurate Esters From Wheat Bran.

Frontiers in bioengineering and biotechnology

Jocquel C, Muzard M, Plantier-Royon R, Rémond C.
PMID: 33898404
Front Bioeng Biotechnol. 2021 Apr 07;9:647442. doi: 10.3389/fbioe.2021.647442. eCollection 2021.

Alkyl glycosides and sugars esters are non-ionic surfactants of interest for various applications (cosmetics, food, detergency,…). In the present study, xylans and cellulose from wheat bran were enzymatically converted into pentyl xylosides and glucose and xylose laurate monoesters. Transglycosylation...

Cite
Jocquel C, Muzard M, Plantier-Royon R, et al. An Integrated Enzymatic Approach to Produce Pentyl Xylosides and Glucose/Xylose Laurate Esters From Wheat Bran. Front Bioeng Biotechnol. 2021;9:647442doi: 10.3389/fbioe.2021.647442.
Jocquel, C., Muzard, M., Plantier-Royon, R., & Rémond, C. (2021). An Integrated Enzymatic Approach to Produce Pentyl Xylosides and Glucose/Xylose Laurate Esters From Wheat Bran. Frontiers in bioengineering and biotechnology, 9647442. https://doi.org/10.3389/fbioe.2021.647442
Jocquel, Chloé, et al. "An Integrated Enzymatic Approach to Produce Pentyl Xylosides and Glucose/Xylose Laurate Esters From Wheat Bran." Frontiers in bioengineering and biotechnology vol. 9 (2021): 647442. doi: https://doi.org/10.3389/fbioe.2021.647442
Jocquel C, Muzard M, Plantier-Royon R, Rémond C. An Integrated Enzymatic Approach to Produce Pentyl Xylosides and Glucose/Xylose Laurate Esters From Wheat Bran. Front Bioeng Biotechnol. 2021 Apr 07;9:647442. doi: 10.3389/fbioe.2021.647442. eCollection 2021. PMID: 33898404; PMCID: PMC8058420.
Copy Download .nbib Format: NLM
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable...

Cite
Trinh A, Khamari R, Fovez Q, et al. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021;55:101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 55101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells." Molecular metabolism vol. 55 (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941.
Copy Download .nbib Format: NLM
Chronic binge alcohol and ovariectomy dysregulate omental adipose tissue metaboproteome in simian immunodeficiency virus-infected female macaques.

Physiological genomics

Poret JM, Guidry JJ, Simon L, Molina PE.
PMID: 34252326
Physiol Genomics. 2021 Aug 01;53(8):358-371. doi: 10.1152/physiolgenomics.00001.2021. Epub 2021 Jul 12.

Effective antiretroviral therapy (ART) has significantly reduced mortality of people living with HIV (PLWH), and the prevalence of at-risk alcohol use is higher among PLWH. Increased survival and aging of PLWH is associated with increased prevalence of metabolic comorbidities...

Cite
Poret JM, Guidry JJ, Simon L, et al. Chronic binge alcohol and ovariectomy dysregulate omental adipose tissue metaboproteome in simian immunodeficiency virus-infected female macaques. Physiol Genomics. 2021;53(8):358-371doi: 10.1152/physiolgenomics.00001.2021.
Poret, J. M., Guidry, J. J., Simon, L., & Molina, P. E. (2021). Chronic binge alcohol and ovariectomy dysregulate omental adipose tissue metaboproteome in simian immunodeficiency virus-infected female macaques. Physiological genomics, 53(8), 358-371. https://doi.org/10.1152/physiolgenomics.00001.2021
Poret, Jonquil M, et al. "Chronic binge alcohol and ovariectomy dysregulate omental adipose tissue metaboproteome in simian immunodeficiency virus-infected female macaques." Physiological genomics vol. 53,8 (2021): 358-371. doi: https://doi.org/10.1152/physiolgenomics.00001.2021
Poret JM, Guidry JJ, Simon L, Molina PE. Chronic binge alcohol and ovariectomy dysregulate omental adipose tissue metaboproteome in simian immunodeficiency virus-infected female macaques. Physiol Genomics. 2021 Aug 01;53(8):358-371. doi: 10.1152/physiolgenomics.00001.2021. Epub 2021 Jul 12. PMID: 34252326; PMCID: PMC8409904.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries